EE05088B1 - Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine - Google Patents
Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamineInfo
- Publication number
- EE05088B1 EE05088B1 EEP200200545A EEP200200545A EE05088B1 EE 05088 B1 EE05088 B1 EE 05088B1 EE P200200545 A EEP200200545 A EE P200200545A EE P200200545 A EEP200200545 A EE P200200545A EE 05088 B1 EE05088 B1 EE 05088B1
- Authority
- EE
- Estonia
- Prior art keywords
- cabergoline
- solvate
- obtaining
- preparation
- crystalline form
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title 2
- 229960004596 cabergoline Drugs 0.000 title 2
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007308.0A GB0007308D0 (en) | 2000-03-24 | 2000-03-24 | Process for preparing crystalline form | of cabergoline |
| PCT/EP2001/003099 WO2001070740A1 (en) | 2000-03-24 | 2001-03-19 | Process for preparing crystalline form i of cabergoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200200545A EE200200545A (et) | 2004-04-15 |
| EE05088B1 true EE05088B1 (et) | 2008-10-15 |
Family
ID=9888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200545A EE05088B1 (et) | 2000-03-24 | 2001-03-19 | Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6727363B2 (https=) |
| EP (1) | EP1272489B1 (https=) |
| JP (1) | JP4184666B2 (https=) |
| KR (1) | KR100827558B1 (https=) |
| CN (1) | CN1188412C (https=) |
| AR (1) | AR032449A1 (https=) |
| AT (1) | ATE250601T1 (https=) |
| AU (2) | AU780747B2 (https=) |
| BR (1) | BR0109507A (https=) |
| CA (1) | CA2402836A1 (https=) |
| CZ (1) | CZ20023176A3 (https=) |
| DE (1) | DE60100858T2 (https=) |
| DK (1) | DK1272489T3 (https=) |
| EA (1) | EA005928B1 (https=) |
| EE (1) | EE05088B1 (https=) |
| ES (1) | ES2208602T3 (https=) |
| GB (1) | GB0007308D0 (https=) |
| HK (1) | HK1052348B (https=) |
| HU (1) | HUP0300591A3 (https=) |
| IL (2) | IL150985A0 (https=) |
| MX (1) | MXPA02009283A (https=) |
| MY (1) | MY134189A (https=) |
| NO (1) | NO20024321L (https=) |
| NZ (1) | NZ521316A (https=) |
| PE (1) | PE20011140A1 (https=) |
| PL (1) | PL358253A1 (https=) |
| PT (1) | PT1272489E (https=) |
| SI (1) | SI1272489T1 (https=) |
| SK (1) | SK13582002A3 (https=) |
| WO (1) | WO2001070740A1 (https=) |
| ZA (1) | ZA200206045B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| MXPA04008915A (es) * | 2002-03-15 | 2005-06-20 | Pharmacia Corp | Proceso para la preparacion de la forma cristalina 1 de la cabergolina. |
| KR100605794B1 (ko) * | 2002-03-15 | 2006-08-01 | 파마시아 코포레이션 | 카베르골린의 제1형 결정을 제조하는 방법 |
| IL155545A (en) | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| EP1620101A4 (en) * | 2003-05-08 | 2008-07-09 | Ivax Pharmaceuticals Sro | POLYMORPHS OF CABERGOLIN |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| GB0515430D0 (en) * | 2005-07-27 | 2005-08-31 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
| EP2185169A2 (en) * | 2007-08-29 | 2010-05-19 | Max Zeller Söhne AG | Use of vitex agnus castus extracts for preparing a medicament |
| EP4074552B1 (en) * | 2021-04-16 | 2024-04-03 | Thermo King LLC | Electrical connection unit |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3019322A1 (de) | 1980-05-21 | 1981-12-03 | Merck Patent Gmbh, 6100 Darmstadt | Psychopharmakon sowie verwendung von adenosinderivaten |
| US4526892A (en) | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| GB9205439D0 (en) * | 1992-03-12 | 1992-04-22 | Erba Carlo Spa | Process for the synthesis of ergoline derivatives |
| WO1995005176A1 (en) | 1993-08-18 | 1995-02-23 | Alcon Laboratories, Inc. | Use of ergoline derivatives for the treatment of glaucoma |
| EP1075278A1 (en) | 1998-01-13 | 2001-02-14 | AstraZeneca UK Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY |
| SK13312000A3 (sk) | 1998-03-27 | 2001-05-10 | Pharmacia And Upjohn Company | Použitie kabergolínu pri liečbe syndrómu nepokojných nôh |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
-
2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
-
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en not_active Ceased
- 2001-03-19 EP EP01936098A patent/EP1272489B1/en not_active Expired - Lifetime
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 PL PL01358253A patent/PL358253A1/xx not_active Application Discontinuation
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active Expired - Fee Related
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
-
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321L/no not_active Application Discontinuation
-
2003
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
-
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200545A (et) | Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine | |
| CY2007029I1 (el) | Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων | |
| IL155306A0 (en) | Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby | |
| FR2806086B1 (fr) | Base cristalline du citalopram | |
| EE200200470A (et) | Uued ühendid, meetod nende valmistamiseks ning nende kasutamine | |
| HRP20030065A2 (en) | Method for the preparation of citalopram | |
| IL151059A0 (en) | Method for the preparation of citalopram | |
| HUP0300078A3 (en) | Method for the preparation of citalopram | |
| AU2001251083A1 (en) | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists | |
| EE04234B1 (et) | L-fenüülefriinvesinikkloriidi valmistamise meetod | |
| GB0007307D0 (en) | Crystalline form || of cabergoline | |
| IL151467A0 (en) | Method for the preparation of citalopram | |
| GB0007309D0 (en) | Crystalline form V|| of cabergoline | |
| IL151490A0 (en) | Method for the preparation of citalopram | |
| IL152645A0 (en) | Method for the preparation of citalopram | |
| IL148525A0 (en) | Method for the preparation of citalopram | |
| PL346034A1 (en) | Method of obtaining substituted banzoylcyanide aminohydrazones | |
| ITMI20000680A0 (it) | Ciclopentadieni sostituiti policiclici e metodo per la loro preparazione | |
| IL151489A0 (en) | Method for the preparation of citalopram | |
| AU2001264000A1 (en) | Phosphomagnesium mortar and method for obtaining same | |
| PL347056A1 (en) | Novel compounds of heterocycloalkylbezocyclobutane and heterocycloarylbenzocyclobutane, method of obtaining them and pharmacological compositions containming such compounds | |
| EE05218B1 (et) | Meetod distamtsiini derivaadi valmistamiseks | |
| GB0002873D0 (en) | Sample preparation method | |
| PL341634A1 (en) | Method of obtaining derivatives of phenylsulphonylmethyltetrazole | |
| SI1265882T1 (en) | Method for the preparation of citalopram |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20100319 |